Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor

Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study

(2014) Maria-Agata Miselli et al.   Cardiovascular Diabetology

Low Nonfasting Triglycerides and Reduced All-Cause Mortality: A Mendelian Randomization Study

(2014) M. Thomsen et al.   CLINICAL CHEMISTRY

Triglycerides and cardiovascular disease

(2014) Børge G Nordestgaard et al.   LANCET

HDL and cardiovascular disease

(2014) Daniel J Rader et al.   LANCET

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia

(2014) Paloma Almeda-Valdes et al.   BMC Endocrine Disorders

The G-Protein-Coupled Long-Chain Fatty Acid Receptor GPR40 and Glucose Metabolism

(2014) Tsutomu Tomita et al.   Frontiers in Endocrinology

Comparison of Statin Alone Versus Bezafibrate and Statin Combination in Patients With Diabetes Mellitus and Acute Coronary Syndrome

(2013) Robert Klempfner et al.   AMERICAN JOURNAL OF CARDIOLOGY

High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate

(2013) Xunliang Tong et al.   Cardiovascular Diabetology

Pitavastatin in cardiometabolic disease: therapeutic profile

(2013) Luis Masana   Cardiovascular Diabetology

Statins in cardiometabolic disease: what makes pitavastatin different?

(2013) Henry Ginsberg   Cardiovascular Diabetology

Metabolism of plasma cholesterol and lipoprotein parameters are related to a higher degree of insulin sensitivity in high HDL-C healthy normal weight subjects

(2013) Camila C Leança et al.   Cardiovascular Diabetology

Genetic analysis of haptoglobin polymorphisms with cardiovascular disease and type 2 diabetes in the diabetes heart study

(2013) Jeremy N Adams et al.   Cardiovascular Diabetology

Differential impact of metabolic syndrome on subclinical atherosclerosis according to the presence of diabetes

(2013) Ki-Bum Won et al.   Cardiovascular Diabetology

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

(2013) Eliot A Brinton et al.   Cardiovascular Diabetology

Statin diabetogenicity: guidance for clinicians

(2013) Kausik Ray   Cardiovascular Diabetology

Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study

(2013) Tamio Teramoto et al.   Cardiovascular Diabetology

Preclinical atherosclerosis and metabolic syndrome increase cardio- and cerebrovascular events rate: a 20-year follow up

(2013) Salvatore Novo et al.   Cardiovascular Diabetology

High-Density Lipoproteins

(2013) Wijtske Annema et al.   CIRCULATION JOURNAL

Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies

(2013) M. J. Chapman et al.   CURRENT MEDICAL RESEARCH AND OPINION

Common variants associated with plasma triglycerides and risk for coronary artery disease

(2013) Ron Do et al.   NATURE GENETICS

n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia

(2013) Tomoya Mita et al.   Journal of Diabetes Investigation

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management

(2013) Robert A Hegele et al.   Lancet Diabetes & Endocrinology

The metabolic syndrome and progression of carotid atherosclerosis over 13 years. The Tromsø study

(2012) Marit Herder et al.   Cardiovascular Diabetology

Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study

(2012) Xuanqi An et al.   Cardiovascular Diabetology

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction

(2012) Alexander Tenenbaum et al.   Cardiovascular Diabetology

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

(2012) Alexander Tenenbaum et al.   Cardiovascular Diabetology

Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

(2012) Tamio Teramoto et al.   Cardiovascular Diabetology

Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease

(2012) Michel Farnier et al.   Diabetes & Vascular Disease Research

Mortality risk of triglyceride levels in patients with coronary artery disease

(2012) Takatoshi Kasai et al.   HEART

Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events

(2012) Evangelos C. Rizos et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline

(2012) Lars Berglund et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease

(2012) Anette Varbo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Is it time to revise the HDL cholesterol hypothesis?

(2012) Daniel J Rader et al.   NATURE MEDICINE

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data

(2012) Alexander Tenenbaum et al.   PLoS One

Omega-3 Fatty Acids EPA and DHA: Health Benefits Throughout Life

(2012) Danielle Swanson et al.   Advances in Nutrition

Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes

(2011) Lutgarda Bozzetto et al.   ATHEROSCLEROSIS

Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease

(2011) Laura Calabresi et al.   ATHEROSCLEROSIS

FoxO1 integrates insulin signaling to VLDL production

(2011) Adama Kamagate et al.   CELL CYCLE

Triglycerides and Cardiovascular Disease

(2011) Michael Miller et al.   CIRCULATION

Fatty acids acutely enhance insulin-induced oxidative stress and cause insulin resistance by increasing mitochondrial reactive oxygen species (ROS) generation and nuclear factor-κB inhibitor (IκB)–nuclear factor-κB (NFκB) activation in rat muscle, in the absence of mitochondrial dysfunction

(2011) R. Barazzoni et al.   DIABETOLOGIA

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

(2011) M. John Chapman et al.   EUROPEAN HEART JOURNAL

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study

(2010) H.A.W. Neil et al.   ATHEROSCLEROSIS

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study

(2010) Alexander Tenenbaum et al.   Cardiovascular Diabetology

Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects

(2010) Manoj Mathew et al.   Cardiovascular Diabetology

Effects of ethanol intake on lipoproteins and atherosclerosis

(2010) Eliot A Brinton   CURRENT OPINION IN LIPIDOLOGY

Aldosterone, Sodium, and Hypertension

(2010) John W. Funder   HYPERTENSION

Cardiovascular effects of marine omega-3 fatty acids

(2010) Palaniappan Saravanan et al.   LANCET

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

(2010)   LANCET

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

(2010) Min Jun et al.   LANCET

Biological, clinical and population relevance of 95 loci for blood lipids

(2010) Tanya M. Teslovich et al.   NATURE

Combination Lipid Therapy in Type 2 Diabetes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Particle size of apoB-48 carrying lipoproteins in remnant lipoproteins isolated from postprandial plasma

(2010) T. Nakano et al.   ANNALS OF CLINICAL BIOCHEMISTRY

Hypertriglyceridemia and Its Pharmacologic Treatment Among US Adults

(2009) Earl S. Ford et al.   ARCHIVES OF INTERNAL MEDICINE

Harmonizing the Metabolic Syndrome

(2009) K.G.M.M. Alberti et al.   CIRCULATION

Triglycerides as vascular risk factors: new epidemiologic insights

(2009) William B Kannel et al.   CURRENT OPINION IN CARDIOLOGY

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events

(2008) Samia Mora et al.   CIRCULATION

Apolipoprotein C-III: understanding an emerging cardiovascular risk factor

(2008) Esther M. M. Ooi et al.   CLINICAL SCIENCE

Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL

(2008) Anton FH Stalenhoef et al.   CURRENT OPINION IN LIPIDOLOGY

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

(2008) R. Scott et al.   DIABETES CARE

Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials

(2008) A. Pandor et al.   JOURNAL OF INTERNAL MEDICINE